A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol
PLOS One · 2026
DOI: 10.1371/journal.pone.0342387 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS One, 2026. Verfasst von Tomoya Kurokawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Chiba University Hospital, Chiba, Chiba, Japan. Hauptthemen laut MEDLINE: Dendritic Cells, Galactosylceramides, Head and Neck Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Natural killer T (NKT) cells show intense tumor-killing activity through direct and indirect pathways. However, humans have less than 0.01% of NKT cells in the peripheral blood, making it difficult to apply NKT cells for cancer treatment. We have successfully produced invariant NKT cells derived from induced pluripotent stem cells (iPSC-iNKT cells) and demonstrated the tolerability of this product in a previous phase 1 clinical trial. Although the iPSC-iNKT cells showed substantial anti-tumor activity against various tumor cell types when combined with α-Galactosylceramide-pulsed autologous dendritic cells (DC/Gal) in non-clinical experiments, the tolerability of this combination therapy for humans has not demonstrated yet. Thus, we planned this first-in-human phase 1 open-label clinical trial to demonstrate data on tolerability and safety, as well as explore the immunological changes that occur following this combination treatment. We hypothesize that the sequential induction of nasal submucosal DC/Gal injection and intra-arterial administration of the iPSC-iNKT cells is tolerable and has a favorable safety profile for cancer patients. This trial provides vital and fundamental information for next-phase clinical trials and future applications of iPSC-iNKT cells for various cancer patients (jRCTa030220741; URL: https://jrct.mhlw.go.jp/en-latest-detail/jRCTa030220741 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Research Center, Chiba University Hospital, Chiba, Chiba, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
- Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.
- Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
ORCID-Profile: Tomoya Kurokawa, Shinichiro Motohashi
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Kurokawa, T., Iinuma, T., Ebisu, H., Yanagidaira, T., Inaba, Y., Fujiwara, T., Hattori, Y., Fukazawa, T., Aoki, T., Koseki, H., Hanaoka, H., Hanazawa, T., & Motohashi, S. (2026). A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol. PLOS One. https://doi.org/10.1371/journal.pone.0342387
Vancouver
Kurokawa T, Iinuma T, Ebisu H, Yanagidaira T, Inaba Y, Fujiwara T, et al. A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol. PLOS One. 2026. doi:10.1371/journal.pone.0342387
BibTeX
@article{Kurokawa2026,
author = {Kurokawa, Tomoya and Iinuma, Tomohisa and Ebisu, Haruna and Yanagidaira, Tomoha and Inaba, Yosuke and Fujiwara, Tadami and Hattori, Yoko and Fukazawa, Tominaga and Aoki, Takahiro and Koseki, Haruhiko and Hanaoka, Hideki and Hanazawa, Toyoyuki and Motohashi, Shinichiro},
title = {A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0342387}
}
EUVIMED